Outcomes of the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP)


Process for proposed COVID-19 treatments

Once a treatment is submitted, UKRI collates evidence and data on the compound. This information is provided by:

  • academics
  • clinicians
  • industry experts
  • published literature
  • other independent sources.

A team of due diligence managers validates the information and develops a briefing document for the relevant UK-CTAP sub-panel.

The sub-panels consider the briefs and provide advice on the treatments to either:

UK-CTAP and POG meet to consider the advice, briefs and any other information on the treatments. This group then makes a recommendation to CMO England and the principal investigators for each trial.

CMO England and the principal investigators then decide which treatments are entered into clinical trials.

For information on trial results, see:

Last updated: 6 May 2021

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services.